Johnson & Johnson’s JNJ third-quarter 2024 earnings came in at $2.42 per share, which beat the Zacks Consensus Estimate of $2.22. Earnings declined 9% from the year-ago period. Adjusted earnings ...
(Reuters) -Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug ...
Johnson & Johnson’s JNJ fourth-quarter 2024 earnings came in at $2.04 per share, which beat the Zacks Consensus Estimate of $2.00. Earnings declined 10.9% from the year-ago period. Adjusted earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results